.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01C_BetaLactamAntibacterialsPenicillins.J01CR02_AmoxicillinAndBetaLactam.AmoxicillinAndBetaLactam .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01C_BetaLactamAntibacterialsPenicillins.J01CR02_AmoxicillinAndBetaLactam.AmoxicillinAndBetaLactam| name: | AmoxicillinAndBetaLactamaseInhibitor |
| ATC code: | J01CR02 | route: | oral |
| n-compartments | 1 |
A combination antibacterial medication consisting of amoxicillin, a broad-spectrum penicillin antibiotic, and a beta-lactamase inhibitor (commonly clavulanic acid), which extends the spectrum of amoxicillin by inhibiting bacterial beta-lactamase enzymes. It is approved and widely used today for the treatment of infections such as respiratory tract infections, urinary tract infections, skin infections, and others caused by susceptible bacteria.
Pharmacokinetic parameters in healthy adult volunteers after a single oral administration of amoxicillin in combination with clavulanic acid.
Mellon, G, et al., & Crémieux, AC (2020). Population pharmacokinetics and dosing simulations of amoxicillin in obese adults receiving co-amoxiclav. The Journal of antimicrobial chemotherapy 75(12) 3611–3618. DOI:10.1093/jac/dkaa368 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32888018
Schouwenburg, S, et al., & Preijers, T (2025). A Pooled Population Pharmacokinetic Study of Oral and Intravenous Administration of Clavulanic Acid in Neonates and Infants: Targeting Effective Beta-Lactamase Inhibition. Clinical pharmacology and therapeutics 117(1) 193–202. DOI:10.1002/cpt.3423 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39205386
de Velde, F, et al., & Mouton, JW (2016). Non-linear absorption pharmacokinetics of amoxicillin: consequences for dosing regimens and clinical breakpoints. The Journal of antimicrobial chemotherapy 71(10) 2909–2917. DOI:10.1093/jac/dkw226 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27330071